Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
15,938,643
-
Total 13F shares
-
234,640
-
Share change
-
-55,036
-
Total reported value
-
$149,046
-
Price per share
-
$0.63
-
Number of holders
-
12
-
Value change
-
-$82,917
-
Number of buys
-
6
-
Number of sells
-
4
Institutional Holders of ADIAL PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (ADIL) as of Q1 2025
As of 31 Mar 2025,
ADIAL PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (ADIL) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
234,640 shares.
The largest 10 holders included
GEODE CAPITAL MANAGEMENT, LLC, Manchester Capital Management LLC, UBS Group AG, BlackRock, Inc., Virtu Financial LLC, VANGUARD GROUP INC, Tower Research Capital LLC (TRC), SBI Securities Co., Ltd., WELLS FARGO & COMPANY/MN, and BANK OF AMERICA CORP /DE/.
This page lists
12
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.